Drug adherence to biologic DMARDs with a special emphasis on the benefits of subcutaneous abatacept

Anshuman P Malaviya
Andrew JK Östör

1Rheumatology Clinical Research Unit, Addenbrooke’s Hospital, Cambridge, UK; 2School of Clinical Medicine, University of Cambridge, Cambridge, UK

Abstract: Major advances in drug development have led to the introduction of biologic disease-modifying drugs for the treatment of rheumatoid arthritis, which has resulted in unprecedented improvement in outcomes for many patients. These agents have been found to be effective in reducing clinical signs and symptoms, improving radiological damage, quality of life, and functionality, and have also been found to have an acceptable safety profile. Despite this, drug adherence is unknown, which has huge health care and health-economic implications. Local and national guidelines exist for the use of biologics; however, its varied use is widespread. Although this may in part reflect differences in prescribing behavior, patient preference plays a key role. In this review we will explore the factors that contribute to patient preference for, and adherence to, biologic therapy for rheumatoid arthritis with emphasis on the subcutaneous preparation of abatacept, a T-cell costimulatory molecule blocker. Overall, subcutaneous administration is preferred by patients and this may well improve drug adherence.

Keywords: subcutaneous administration, self-injectable, abatacept, rheumatoid arthritis, preference, adherence, compliance, biologic DMARD

Introduction

Over the last 15 years, a transformation in the therapeutic landscape of rheumatoid arthritis (RA) has been seen with a number of highly efficacious drugs having become available. The expense of drug development coupled with a restricted market has influenced the cost of these medications, with the average biologic disease-modifying antirheumatic drug (bDMARD) costing around £10,000 per annum in the United Kingdom. It is therefore essential that these newer therapies are acceptable to patients, and that adherence is maintained. In light of this, there has been considerable interest in determining the factors that contribute to both patient preference for and adherence to medications.

The complex and poorly understood field of drug adherence represents an enormous health care challenge. The World Health Organization suggests that <50% of patients with chronic illness take their therapies as prescribed, and up to 30% of prescriptions in the United States are never filled.1,2 Nonadherence to medication is associated with greater morbidity and mortality in chronic diseases.3–5 Furthermore, nonadherence has been found to be quite costly to health care, with estimates suggesting an additional $170 billion annually in the US has been spent as a consequence of nonadherence.6 Patient adherence to bDMARDs is difficult to evaluate, and the results from studies that have explored this area are unclear. In Crohn’s disease, for instance, nonadherence to intravenous infliximab maintenance therapy has been estimated to be 34% in...
the first year. Given that infliximab is administered as an 8-weekly intravenous infusion (compared with etanercept and adalimumab, which are weekly and fortnightly subcutaneous injections, respectively), it appears that adherence does not appear to be much better for intravenous therapy than other modes of administration.

In light of this, we undertook a review to explore adherence to bDMARDs in patients with RA. Since the terms “compliance,” “adherence,” “concordance,” and “persistence” are often used interchangeably, we have restricted our discussion to adherence (see Table 1 for definitions of terms), while taking into account the factors influencing preference for biologic therapies in patients with RA. In addition, we have summarized the trial evidence for abatacept use in RA, and have highlighted the potential advantages of a self-injectable, subcutaneous (SC) form of the drug.

**Pharmacotherapy for RA**

**Adherence to treatment in rheumatoid arthritis**

A number of critical issues appear to influence patient adherence to therapies. These include patient- and physician-specific factors as well as treatment-associated factors (Figure 1). "Self-efficacy" (defined as an individual’s belief that current health behaviors will impact future health) appears to play an important role. Social support, level of education, and age also contribute to adherence. Furthermore, drug tolerability appears to affect adherence to pharmacotherapy. For example, many conventional DMARDs are deemed to be well-tolerated; however, data exists to the contrary. Gispen et al provided follow-up after 1 year for 72 patients with RA who were receiving oral methotrexate. They described that minor side-effects (oral ulcers, transient elevation of liver enzymes, and nausea) were seen in 64% of patients. Despite the importance of this, more recent data on the subject is lacking.

Adherence to biologic therapy is poorly understood since most studies have investigated drug persistence, which represents only a surrogate of adherence. It has been found that persistence with anti-TNF (tumor necrosis factor) therapy varies from 20% at 36 months for infliximab to 89% at 6 months for unselected TNF antagonists. The reasons for this are multifactorial, and include primary and secondary inefficacy, as well as degree of tolerability. It should be noted that persistence data from prospective clinical trials is inherently biased and does not necessarily reflect real-life experience. Studies have also used medication possession ratio and administrative claims data to measure adherence. For instance, the Danish biologics registry (DANBIO), which is following patients who are taking infliximab, adalimumab, and etanercept, suggests that patients receiving infliximab had the lowest rates of drug adherence, although the methods used to assess this were not specified. A further study by Li et al which looked at drug switching, discontinuation, and adherence in Medicaid patients with RA after 12 months of biologic therapy, used “proportion of days covered” (PDC) as a measure of adherence. Those patients receiving anakinra (an IL-1 receptor antagonist) were found to be the least adherent (PDC 0.36), whereas infliximab users were the most adherent (PDC 0.64). Harley et al found compliance to be higher in patients receiving infliximab when compared with etanercept. A further study exploring patients who were prescribed adalimumab and etanercept demonstrated a marked reduction in drug adherence, which was associated with higher out-of-pocket costs. Although this may be a critical issue in certain parts of the world, out-of-pocket expenses are less relevant in the UK. Despite this, adherence to biologic therapy is far from ideal and is affected by a number of factors, some of which have yet to be defined.

**Preference for biologic therapy in rheumatoid arthritis**

With an array of different bDMARDs having similar efficacy and tolerability, patient preference is of major importance in the treatment decision. In one study focusing on preference for anti-TNF therapy, most patients preferred the subcutaneous mode of administration over intravenous and intramuscular administration (41% of patients on anti-TNF drugs and 56% of those not on anti-TNFs preferred

---

**Table 1 Definitions of adherence, compliance, concordance, and persistence**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Compliance</td>
<td>The extent to which the patient’s behavior matches the prescriber’s recommendations. There is an implied lack of patient involvement.</td>
</tr>
<tr>
<td>2. Adherence</td>
<td>The extent to which the patient continues the agreed-upon mode of treatment under limited supervision when faced with conflicting demands.</td>
</tr>
<tr>
<td>3. Concordance</td>
<td>Encompasses the process in which doctor and patient agree therapeutic decisions that incorporate their respective views, to a wider concept which stretches from prescribing communication to patient support in medicine taking.</td>
</tr>
<tr>
<td>4. Persistence</td>
<td>This refers to the duration of time that the patient continues a specified therapy and may or may not have conformed to the dosing schedule during that time.</td>
</tr>
</tbody>
</table>
This diversity in attitudes towards and influences affecting treatment preference and adherence further indicates that no single factor universally affects patient preference.

**T-lymphocyte costimulation blockade with abatacept**

Abatacept (Orencia Bristol Myers Squibb) is a novel bDMARD licensed for use in the treatment of RA and juvenile idiopathic arthritis. It is a costimulatory molecule blocker which inhibits the activation of T-cells. Abatacept consists of an Fc portion of immunoglobulin, which is attached to the extra-cellular domain of cytotoxic T-lymphocyte antigen-4 (Figure 2). Activation of T-cells requires binding of the T-cell receptor to the antigen-major histocompatibility complex on the antigen-presenting cell (APC) and costimulation including CD28 (on the T-cell) binding to CD80/86 on the APC. Abatacept has a high affinity for CD80/86 and thus inhibits T cell co-stimulation and activation. Abatacept is administered intravenously (10 mg/kg) monthly after initial loading; however, a subcutaneous preparation (125 mg weekly after an initial intravenous loading dose) has also been approved by the Food and Drug Administration for moderate to severe RA.

**Efficacy of intravenous abatacept**

A number of Phase 3 randomized controlled trials have been undertaken with abatacept. These include AIM (Abatacept in Inadequate responders to Methotrexate); ATTAIN (Abatacept Trial in Treatment of Anti-TNF

---

**Figure 1** Factors that influence adherence to treatment in patients with rheumatoid arthritis.

---

---
Radiological outcomes also improved in the active arm and were sustained over the course of long-term treatment.

ATTAIN was a randomized, placebo-controlled trial aimed at assessing the efficacy and tolerability of abatacept in patients who had an inadequate response to anti-TNF therapy. Patients were randomized to receive abatacept or placebo in addition to bDMARD therapy. At 6 months, the ACR20 response rates were 50% in the abatacept-treated group when compared to 19.5% in the placebo group ($P < 0.001$). Patients who received treatment demonstrated statistically significant response rates when compared to the placebo group at 6 months.

The ATTEST study was a comparator trial with three arms – abatacept, infliximab, or placebo – on a background of MTX. The trial, however, was not powered to distinguish between the effects of abatacept and infliximab on RA outcomes. Both active arms demonstrated statistically significant improvement in ACR response rates when compared to placebo, and, interestingly, the response rates appeared to be consistently higher for abatacept than for infliximab.

The ADJUST study was designed to determine the effects of abatacept in early undifferentiated arthritis or very early rheumatoid arthritis. 50 patients were recruited to this Phase 2 study and were randomized to receive either abatacept or placebo for 6 months. The primary end point was the development of RA at 12 months. Fewer patients in the abatacept group (12/26 or 46%) progressed to RA when compared with the placebo group (16/24 or 67%). However, the difference between the two groups did not achieve statistical significance. Similar improvements in the active group were seen in modified Sharp scores and magnetic resonance imaging erosion scores, but again these results did not achieve statistical significance.

Finally, the AGREE study was a multinational, randomized, placebo-controlled trial comparing the efficacy of the combination of abatacept and methotrexate in patients who were methotrexate naïve. The primary end point was a disease activity score of 28 and remission at 12 months. 41% of patients achieved this end point when compared to 23% of controls ($P < 0.001$). Statistically significant differences were also noted in the proportion of patients achieving ACR50 and ACR70, and in radiological outcomes in the active arm.

**Efficacy of subcutaneous abatacept in RA**

The efficacy and safety of SC abatacept has been trialed in two Phase 3B randomized controlled trials (ACQUIRE and ALLOW) [evaluation of Abatacept administered subcutaneously in inadequate Responders to methotrexate]. The trials, however, were not powered to distinguish between the effects of abatacept and infliximab on RA outcomes. Both active arms demonstrated statistically significant improvement in ACR response rates when compared to placebo, and, interestingly, the response rates appeared to be consistently higher for abatacept than for infliximab.
with active rheumatoid arthritis: impact of Withdrawal and reintroduction on immunogenicity, efficacy and safety\textsuperscript{29} and two Phase 3B open-labeled studies (ATTUNE\textsuperscript{29} and ACCOMPANY\textsuperscript{30}, ACQUIRE was a Phase 3 noninferiority study comparing the safety and efficacy of SC abatacept with the IV formulation over 6 months. The ACR and disease activity score remission responses are outlined in Table 2. No significant differences were seen in the two groups, with ACR20 response rates of 76% in the SC group and 75.8% in the IV group. The trial has revealed that SC abatacept demonstrates comparable efficacy to the IV formulation and also has a high retention rate.

Another Phase 3B trial (ALLOW) studied the effects of temporary cessation of SC abatacept on immunogenicity, side-effects, and efficacy. Drug withdrawal for 3 months followed by reintroduction was not associated with increased immunogenicity, and no safety or efficacy concerns were identified.

The ACCOMPANY study\textsuperscript{30} looked at the safety and efficacy of SC abatacept without an IV loading dose. At 12 weeks no statistically significant differences were seen, suggesting that the IV loading may not be an absolute prerequisite.

### Safety and tolerability of abatacept in RA

In a pooled analysis of a number of randomized controlled trials using abatacept (4764 patient-years of exposure), the rate of adverse events, serious adverse events, and malignancy rates were no different between the abatacept and the placebo-treated groups.\textsuperscript{31} To date, no flags have been raised in relation to abatacept’s association or impact on heart failure and malignancy.\textsuperscript{31} In addition, the immunogenicity of IV abatacept in the pooled analysis was not found to be associated with loss of efficacy or adverse events.\textsuperscript{29} Literature suggests that the likelihood of an immune response to a biologic agent is greater after SC administration than after an IV infusion.\textsuperscript{32} Data from the ALLOW study demonstrated that SC abatacept was not more immunogenic than the IV preparation.\textsuperscript{28} Injection-site reactions were reported among two patients in the initial phase of the study. The reactions were mild and did not appear to recur when the drug was reintroduced later in the study.

Long-term extension data from one trial has demonstrated acceptable patient tolerability and efficacy of abatacept lasting up to 5 years.\textsuperscript{33} Infusion reactions in the IV abatacept studies have been seen in 9% of actively treated patients when compared with 6% of controls; however, overall these

### Table 2 Key clinical trial data for intravenous and subcutaneous abatacept in the treatment of RA

<table>
<thead>
<tr>
<th>Study name (study duration)</th>
<th>Key features</th>
<th>n</th>
<th>Results*</th>
<th>Improved radiological outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies with intravenous abatacept</strong></td>
<td></td>
<td></td>
<td>ACR 20 (control arm)</td>
<td>ACR 50 (control arm)</td>
</tr>
<tr>
<td>AIM\textsuperscript{1} (12 months)</td>
<td>ABT + MTX versus MTX alone in MTX-inadequate responders</td>
<td>652</td>
<td>73 (40)</td>
<td>48 (18)</td>
</tr>
<tr>
<td>Kremer et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATTEST\textsuperscript{2} (12 months)</td>
<td>MTX failure: abatacept or infliximab active arms</td>
<td>431</td>
<td>72 (56)\textsuperscript{2}</td>
<td>46 (36)\textsuperscript{2}</td>
</tr>
<tr>
<td>Schiff et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATTAIN\textsuperscript{3} (6 months)</td>
<td>ABT + MTX versus MTX alone in anti-TNF inadequate responders</td>
<td>391</td>
<td>50 (20)</td>
<td>20 (4)</td>
</tr>
<tr>
<td>Genovese et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGREE (12 months)</td>
<td>ABT + MTX in MTX-naïve patients with RA</td>
<td>509</td>
<td>–</td>
<td>57 (42)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADJUST\textsuperscript{4} (Phase 2-6 months)</td>
<td>ABT versus placebo in early undifferentiated anti-CCP positive arthritis</td>
<td>50</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Studies with subcutaneous abatacept</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACQUIRE\textsuperscript{1} (6 months)</td>
<td>SC ABT versus IV ABT</td>
<td>1457</td>
<td>76 (75.8)\textsuperscript{a}</td>
<td>50 (49)\textsuperscript{a}</td>
</tr>
<tr>
<td>Genovese et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: The control arm shows the response rates with infliximab. The response rates for the placebo arm are not shown; *Noninferiority study with IV ABT as the control arm. Figures represent the percentages of patients achieving ACR/DAS responses in the intention-to-treat population.

Abbreviations: n, number; ACR, American College of Rheumatology; DAS, disease activity score; ABT, abatacept; MTX, methotrexate; TNF, tumor necrosis factor; RA, rheumatoid arthritis; CCP, anti-cyclic citrullinated protein antibody; SC, subcutaneous; IV, intravenous.
effects were mild. Combined data from five RCTs has suggested that the risk of serious infections is 3% compared to 1.9% in the placebo groups. Interestingly, a Cochrane safety review suggested that abatacept had a better safety profile than most other biologics. This data pertains to IV abatacept; however, it is reassuring that data from the SC abatacept studies indicates that SC abatacept is at least as safe as IV abatacept.

Pharmacoeconomics
Although clinical effectiveness (quality, efficacy, and tolerability) of any new pharmacotherapy is paramount, it is increasingly necessary that cost-effectiveness is demonstrated as well. This is particularly relevant to biologic therapy in RA, where a number of drugs are available. Cost of therapy is even more important when treatment is privately funded. Cost-effectiveness is affected by a number of factors, not least of which is drug adherence. A study looking at the cost-effectiveness of osteoporosis therapy concluded that the cost per quality-adjusted life year increased from €4871 (assuming full compliance and medicine possession ratio of 100%) to €30,181 if compliance (measured by medicine possession ratio) fell to 60%. This clearly demonstrates the impact of drug adherence on cost-effectiveness and drugs that can demonstrate higher adherence are likely to be more cost-effective.

The need for monthly infusions and the resulting higher relative cost of IV abatacept has limited its use in the UK to patients with RA who have failed (or not tolerated) anti-TNFs and rituximab. Introduction of SC abatacept will certainly impact upon its cost-effectiveness both by negating the need for infusions and by promoting potentially higher adherence. As a result, it is likely that, in the future, the UK National Institute for Health and Clinical Excellence will rule in favor of earlier use of SC abatacept.

“Oral” biologics
Recently there has been considerable interest in oral “small molecules” that bind to specific intracellular receptors thereby influencing the proinflammatory cascade. A number of molecules have been studied in Phase 2 and 3 clinical trials. Some of these newer drugs have demonstrated levels of efficacy that are comparable to anti-TNF therapies. A recent Phase 2B study comparing the efficacy of tofacitinib (an inhibitor of Janus kinase-3 enzyme which interferes with the JAK-STAT intra-cellular signaling pathway) with adalimumab demonstrated similar efficacy of the two drugs when used as monotherapy.

Fostimatinib, a spleen tyrosine kinase inhibitor, showed promise in initial trials; however, recent reports suggest that it may be no more effective than placebo in patients who have previously failed biologic therapy. Mitogen-activated protein kinase inhibitors are another promising group of drugs. However, current data from human studies have demonstrated a potentially unacceptable side-effect profile with hepatotoxicity and gastrointestinal side-effects. While these effects are almost certainly more acceptable to patients than parenteral therapy, the true role of these oral ‘biologics’ in the treatment of RA remains to be seen.

Conclusion
Although the search for the optimal therapy for RA continues, parenteral administration is unlikely to diminish in the short to medium term. bDMARDs such as abatacept, with well-established efficacy, safety, and tolerability will continue to form an integral part of the treatment paradigm. The SC, self-injectable form of abatacept is effective and well-tolerated and is certainly a welcome addition to the therapeutic armamentarium for RA. In our opinion, it will be well-received by patients, thereby improving adherence and treatment outcomes for patients living with this previously crippling disease.

Disclosure
Dr Malaviya’s clinical research fellowship is funded by CARE (Cambridge Arthritis Research Endeavour). Andrew Östör has received support from, attended conferences by, undertakes clinical trials with, and acts as a consultant to Roche, Chugai, MSD, Abbott, Pfizer, BMS, GSK, Merck-Sorono, and UCB.

References